Biotechnology
Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity
- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models. - ASC39 demonstrated eloralintide-like selectivity for human amylin 1 receptor (hAMY1R) over human calcitonin receptor (hCTR) (40-fold), support...
2026-10-26 08:10
771
Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026
SHANGHAI and HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-10-26 08:00
521
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
* Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89; one-sided P = 0.0021). * The 2-year OS rate was 54.1% vs 37.2%, an improvement of 16.9%; with a median follow-u...
2026-10-25 19:12
2492
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
* PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001 ), and median PFS was 15.0 months (95% CI 9.9-NE) and 5.7 months (95% CI 5.5-7.4) in the two groups, respectively. * Responses were more dur...
2026-10-25 18:44
3026
Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026
BEIJING, Oct. 24, 2026 /PRNewswire/ -- Likang Life Sciences ("Likang"), a biotechnology company advancing AI-enabled personalized cancer immunotherapies, sponsored and exhibited at the Abu Dhabi Future Health Summit 2026, held from 20 to 22 October at ADNEC Centre Abu Dhabi. The summit marked a m...
2026-10-24 19:38
6536
Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO
CHENGDU, China, Oct. 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, updated results from the Phase II MK-2870-002/SKB264-II-06 ...
2026-10-24 18:15
6706
19th EU-China Business Meeting Concludes! Third-Generation Triple-Helix Biomimetic Collagen Medical Devices Make Their Global Debut, Highlights from the Event
CHENGDU, China, Oct. 24, 2026 /PRNewswire/ -- At the 19th EU-China Business Meeting, co-hosted by the China Chamber of International Commerce (CCOIC) and the European Union Chamber of Commerce in China (EUCCC) in Chengdu, LivingPHOENIX Regenerative Technology Development (Chengdu) Co., Ltd. (her...
2026-10-24 09:29
7334
Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
- At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate of 81.9% (n=33) in 1L ES-SCLC - Among patients with at least six-months follow-up (n=15) treated at...
2026-10-23 20:04
2511
Alebund Pharmaceuticals Announces Poster Presentation by Partner R1 Therapeutics of Global Phase IIb Multi-Regional Clinical Trial Design for AP306 at ASN Kidney Week 2026
SHANGHAI, Oct. 23, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that its partner, R1 Therapeutics, Inc. ("R1"), presented a trial-in-progress poster outlining the design of the ...
2026-10-23 19:00
3056
Angel Yeast Marks 40th Anniversary, Setting Its Sights on Becoming a Global Biotech Powerhouse
YICHANG, China, Oct. 23, 2026 /PRNewswire/ -- Angel Yeast
2026-10-23 18:10
2341
Carnyx Therapeutics Unveils Oral Sleep Candidate CNYX-005 with Preclinical Data Showing Increased NREM Sleep
Preclinical study shows 1.5- to 2-hour increase in total sleep time as Company
advances toward clinical development and attracts Chris Brearley, M.D., as
Chief Medical Officer
INDIANAPOLIS, Oct. 23, 2026 /PRNewswire/ -- Carnyx Therapeutics Ltd.
2026-10-23 08:30
2393
Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
- With first patient dosed in Phase III clinical trial, Ascletis' strategic partner Sagimet Biosciences Inc. ("Sagimet") advances denifanstat (ASC40)'s U.S. registrational program, building on positive Phase III clinical results in China from Ascletis - Pivotal trial designed to enroll approxima...
2026-10-23 08:10
3016
Johnson & Johnson Deepens its Long-Term Commitment to Hong Kong Through OASES Strategic Enterprise Collaboration
Building on more than five decades in Hong Kong, Johnson & Johnson is committed to advancing better health through science, innovation and collaboration for patients and communities in Hong Kong. The partnership will help strengthen clinical research, develop future healthcare talent and su...
2026-10-22 23:52
3589
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
* GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. * Georgiamune to receive $45 million in upfront and near-term payments, as part of a total deal value of up to $1.1 billion, plus royalties. FLORENCE, It...
2026-10-22 22:30
3580
ZEISS announces availability of CT LUCIA 621P in Japan, expanding its broad ZEISS Cataract Workflow
The ZEISS CT LUCIA 621P monofocal intraocular lens (IOL) is added to the ZEISS Cataract Workflow in the Japanese market, supporting good visual outcomes for patients. JENA, Germany and TOKYO, Oct. 22, 2026 /PRNewswire/ -- ZEISS Medical Technology announced today the commercial availability of th...
2026-10-22 21:00
1463
Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa
SD-101 (Zorblesia™) is the First Topical Therapy Being Developed to Treat Wounds and Lesions Across the Entire Skin Surface in Patients with Three Major Subtypes of Epidermolysis Bullosa MOUNT PLEASANT, S.C., Oct. 22, 2026 /PRNewswire/ -- Paradigm Therapeutics, Inc., a clinical-stage biopharmace...
2026-10-22 20:00
1785
Tairex Launches Multi-Agent AI System to Transform Clinical Collaboration and Decision Support
BEIJING, Oct. 22, 2026 /PRNewswire/ -- Tairex, an AI healthcare technology company incubated by the Institute for AI Industry Research (AIR) at Tsinghua University,unveiled on October 21 the Multidisciplinary Human-Agent Collaboration (MHAC) Ecosystem for Agent Hospital, designed to enable speci...
2026-10-22 17:00
1844
[China's Voice] Preclinical Animal Study: Domestic Neurointerventional Robotic System PANVIS STAR® Completes Validation of Five Major Neurointerventional Procedures
SHANGHAI, Oct. 22, 2026 /PRNewswire/ -- Neurointerventional robots have long remained at the stage of "only being able to assist with angiography." Through close medical-engineering collaboration with Professor Jianmin Liu's team at Shanghai Changhai Hospital, Shenzhen Institute of Advanced Biome...
2026-10-22 14:11
1767
![[China's Voice] Preclinical Animal Study: Domestic Neurointerventional Robotic System PANVIS STAR® Completes Validation of Five Major Neurointerventional Procedures](https://mmx.prnasia.com/media/MS2016836/20261020003710EDT_image_1.jpg?id=OA3028537&p=medium600)
Indegene Receives Frost & Sullivan's 2026 Global Enabling Technology Leadership Recognition for AI-Powered Pharma Commercialization
Indegene is recognized for combining domain-led AI, knowledge orchestration,
and integrated execution to transform pharmaceutical commercialization
workflows.
SAN ANTONIO, Oct. 22, 2026 /PRNewswire/ -- Frost & Sullivan
2026-10-22 13:30
1685
Taimei Technology and GreenLight Clinical Expand Strategic Partnership at AusBiotech 2026 to Pioneer AI-Native Trial Execution Across Asia-Pacific
GOLD COAST, Australia, Oct. 22, 2026 /PRNewswire/ -- Taimei Technology, a global provider of AI-powered clinical development platforms, and GreenLight Clinical (GLC), a physician-led contract research organization (CRO), today announced an expanded strategic partnership at AusBiotech 2026. Evolvi...
2026-10-22 08:00
3903
Week's Top Stories
Most Reposted
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 294 media titles]
2026-10-22 22:35
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 283 media titles]
2026-10-19 13:18
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 281 media titles]
2026-10-23 21:52
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 276 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
31105
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
26754
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
24661
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
24499